Pulse Biosciences CCO sells 5,000 shares under plan

PULSE BIOSCIENCES, INC.

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised options and sold shares on February 18, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on May 14, 2025.

He exercised stock options for 5,000 shares at an exercise price of $1.53 per share and received 5,000 shares of common stock. He then sold 5,000 common shares in the open market at a weighted average price of $23.64 per share, with individual sale prices ranging from $22.40 to $24.40. After these transactions, he directly owned 43,298 common shares and held 300,000 stock options.

Insider Trade Summary

Exercise and Sale: 5,000 shares ($111K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Danahy Kevin Patrick

Role Chief Commercial Officer

Sold 5,000 shs ($118K)

Approx. gross sale proceeds $118K

Approx. exercise cost $8K

Approx. pre-tax spread $111K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$1.53	$8K
Sale	Common Stock	5,000	$23.64	$118K

Holdings After Transaction: Stock Option (right to buy) — 300,000 contracts (Direct); Common Stock — 43,298 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
2. F2. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
3. F3. Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PLSE Chief Commercial Officer Kevin Patrick Danahy do in this Form 4?

Kevin Patrick Danahy exercised stock options and sold shares of Pulse Biosciences common stock. He exercised options for 5,000 shares, then sold 5,000 shares in open‑market transactions, all executed under a pre‑arranged Rule 10b5‑1 trading plan adopted earlier.

How many Pulse Biosciences (PLSE) shares did the CCO sell and at what price?

He sold 5,000 shares of Pulse Biosciences common stock. The weighted average sale price was $23.64 per share, with actual prices ranging from $22.40 to $24.40, as disclosed, reflecting multiple trades within that price range on the same date.

What stock options did the PLSE CCO exercise in this transaction?

He exercised stock options covering 5,000 shares at an exercise price of $1.53 per share. These options come from a larger grant originally covering up to 450,000 shares of common stock awarded in connection with his promotion in September 2022.

Was the PLSE insider sale by Kevin Danahy under a Rule 10b5-1 plan?

Yes, the sale was executed under a Rule 10b5‑1 trading plan. The filing states the transactions occurred pursuant to a plan that Danahy adopted on May 14, 2025, which pre‑scheduled trades independently of later market conditions.

How many Pulse Biosciences shares and options does the CCO hold after these trades?

After the reported transactions, he directly owned 43,298 shares of common stock and 300,000 stock options. The common shares reflect his remaining equity stake, while the options represent additional potential ownership if exercised in the future.

What are the vesting terms for the PLSE CCO’s option grant mentioned in the Form 4?

The option grant was made on September 23, 2022 for up to 450,000 shares of common stock. According to the disclosure, 25% of the options vest on each anniversary of the grant date, pursuant to an amendment to his employment agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 08:55 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Danahy Kevin Patrick

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		M(1)		5,000	A	$1.53	48,298	D
Common Stock	02/18/2026		S(1)		5,000	D	$23.64(2)	43,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.53	02/18/2026		M(1)			5,000	(3)	09/23/2032	Common Stock	5,000	$0	300,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.

2. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

3. Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.